Journal
ANTIVIRAL RESEARCH
Volume 98, Issue 1, Pages 12-18Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2013.01.002
Keywords
Antiviral; Chikungunya; CHIKV; Homology model; Molecular dynamics; Virtual screening
Categories
Funding
- EU FP7 SILVER [260644]
- KU Leuven GOA [GOA/10/014]
Ask authors/readers for more resources
Chikungunya virus (CHIKV) is an Arbovirus that is transmitted to humans primarily by the mosquito species Aedes aegypti. Infection with this pathogen is often associated with fever, rash and arthralgia. Neither a vaccine nor an antiviral drug is available for the prevention or treatment of this disease. Albeit considered a tropical pathogen, adaptation of the virus to the mosquito species Aedes albopictus, which is also very common in temperate zones, has resulted in recent outbreaks in Europe and the US. In the present study, we report on the discovery of a novel series of compounds that inhibit CHIKV replication in the low mu M range. In particular, we initially performed a virtual screening simulation of similar to 5 million compounds on the CHIKV nsP2, the viral protease, after which we investigated and explored the Structure-Activity Relationships of the hit identified in silico. Overall, a series of 26 compounds, including the original hit, was evaluated in a virus-cell-based CPE reduction assay. The study of such selective inhibitors will contribute to a better understanding of the CHIKV replication cycle and may represents a first step towards the development of a clinical candidate drug for the treatment of this disease. (c) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available